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ABSTRACT
Introduction: Recovery from orthopedic
surgery is oriented towards restoring
functional health outcomes while reducing
hospital length of stay (LOS) and medical
expenditures. Optimal pain management is a
key to reaching these objectives. We sought to
compare orthopedic surgery patients who
received combination intravenous (IV)
acetaminophen and IV opioid analgesia to
those who received IV opioids alone and
compared the two groups on LOS and
hospitalization costs.
Methods: We performed a retrospective
analysis of the Premier Database (Premier, Inc.;
between January 2009 and June 2015)
comparing orthopedic surgery patients who
received post-operative pain management with
combination IV acetaminophen and IV opioids
to those who received only IV opioids starting
on the day of surgery and continuing up to the
second post-operative day. The quarterly rate of
IV acetaminophen use for all hospitalizations
by hospital served as the instrumental variable
in two-stage least squares regressions
controlling for patient and hospital covariates
to compare the LOS and hospitalization costs of
IV acetaminophen recipients to opioid
monotherapy patients.
Results: We identified 4,85,895 orthopedic
surgery patients with 1,74,805 (36%) who had
received IV acetaminophen. Study subjects
averaged 64 years of age and were
predominantly non-Hispanic Caucasians (78%)
and female (58%). The mean unadjusted LOS
for IV acetaminophen patients was 3.2 days
[standard deviation (SD) 2.6] compared to
3.9 days (SD 3.9) with only IV opioids
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(P\0.0001). Average unadjusted
hospitalization costs were $19,024.9 (SD
$13,113.7) for IV acetaminophen patients and
$19,927.6 (SD $19,578.8) for IV opioid patients
(P\0.0001). These differences remained
statistically significant in our instrumental
variable models, with IV acetaminophen
associated with 0.51 days shorter
hospitalization [95% confidence interval (CI)
-0.58 to -0.44, P\0.0001] and $634.8 lower
hospitalization costs (95% CI -$1032.5 to
-$237.1, P = 0.0018).
Conclusion: Compared to opioids alone,
managing post-orthopedic surgery pain with
the addition of IV acetaminophen is associated
with shorter LOS and decreased hospitalization
costs.
Funding: Mallinckrodt Pharmaceuticals.
Keywords: Intravenous (IV); IV
acetaminophen; Opioids; Orthopedic surgery;
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INTRODUCTION
Pain management in the inpatient setting is
generally achieved through the utilization of
prescription opioids or, less commonly,
non-steroidal anti-inflammatory drugs
(NSAIDs). However, in some clinical scenarios,
including in the presence of certain comorbid
cardiac diseases [1, 2] or in patients who have
undergone coronary artery bypass graft surgery
[1, 2], NSAIDs may be contraindicated or less
desirable, and oral acetaminophen is then
commonly used. Among patients on restricted
oral consumption for surgical or metabolic
reasons, however, the treatment options have
historically been limited.
There is also concern that post-operative use
of opioids may lead to long-term use and its
associated consequences [3]. Thus new and
alternative strategies to help minimize opioid
use are being explored. Over the past decade,
multimodal pain management approaches have
been introduced to utilize multiple
pharmacologic and non-pharmacologic
treatments to manage pain [4–6]. This has
extended into the area of orthopedic surgery
with several novel drug developments [7, 8].
Additionally, the recommendation for
multimodal approaches was recently adopted
by guidelines from the American Pain Society
[9].
In November, 2010, an intravenous (IV)
formulation of acetaminophen was approved
by the Food and Drug Administration to
augment clinicians’ choices for multimodal
analgesia and simultaneously address the issue
of managing restricted oral consumption
patients. The overall aim of this study was to
examine the comparative effectiveness of
combination IV acetaminophen (Ofirmev,
Mallinckrodt Pharmaceuticals) and IV opioids
compared to patients receiving monotherapy
with IV opioids following orthopedic surgery.
We sought to estimate the impact of IV
acetaminophen in terms of: length of stay
(LOS), hospitalization costs, inpatient opioid
consumption, and potential opioid-related
complications.
METHODS
We performed a retrospective cohort study
using data from the Premier Database
(Premier, Inc.) between January 1, 2009 and
June 30, 2015. This database contains inpatient
hospitalization service records submitted from
member hospitals across the United States.
Individual patients are linked between
hospitalizations to allow longitudinal analysis
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of multiple hospitalization events per patient
within the same institution. The database
includes medical record-level details of
provider encounters, procedures, and
laboratory work as well as hospitalization-level
details such as International Classification of
Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) diagnosis and procedure codes,
current procedural terminology (CPT) medical
procedure codes, ordered sequencing of events,
and variables describing the costs and charges of
the institution. The staff at Premier diligently
maintains a standardized master charge code
table of all possible events in the database
records and thus all events from provider
encounters to the administration of
medications are captured with codes that are
identifiable across institutions and repeated
hospitalizations.
Inclusion and Exclusion Criteria
We included all patients in the Premier
Database with an orthopedic surgical
procedure (total hip replacement, total knee
replacement, surgical repair of hip fracture, etc.)
who received IV acetaminophen or
monotherapy with IV opioids starting from
the day of surgery and continuing for up to
two additional days during the post-operative
period. All patients in our study cohort with
standardized charge codes for IV opioids and IV
acetaminophen beginning on the day of surgery
(post-operative day zero) through the first two
post-operative days were classified as exposed.
Subjects whose IV acetaminophen use
continued beyond the second post-operative
day were excluded from the analyses to avoid
introducing heterogeneity in the IV
acetaminophen exposed patient population.
Eligible control patients were recipients of IV
opioids without the presence of IV
acetaminophen or IV NSAIDs beginning on
the day of surgery through the second
post-operative day.
We stratified patients into six mutually
exclusive categories: total knee replacement,
total hip replacement, revision of knee
replacement, revision of hip or partial hip
replacement, fracture, or other orthopedic
surgery (spine, shoulder).
Outcomes
We pre-specified four outcomes of interest for
this study: (1) LOS for the surgical procedure
hospitalization, (2) total cost of hospitalization,
(3) mean dose of opioids [calculated in
morphine equivalent doses (MED)], and (4)
surgical complication rates. Total
hospitalization costs and LOS were captured
from the hospitalization summary files. We also
calculated the department-level costs of
hospitalizations among 14 different
departments classified in the Premier Database.
The mean opioid dose was calculated from the
day of surgery through the second
post-operative day. We investigated five groups
of complications: Bowel obstruction, nausea/
vomiting, respiratory depression, surgical site
infection, and urinary tract infection. Each
complication was identified utilizing
ICD-9-DM diagnosis codes, restricted to those
that were classified as not present on admission.
Statistical Analyses
We descriptively compared the IV
acetaminophen recipients to the opioid only
recipients in terms of age, gender, race, all
patient refined-diagnosis related group
(APR-DRG) severity of illness, APR-DRG risk of
mortality, whether the admission was
emergent, and the census region of the
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hospital. We used the Chi-square test (for
categorical variables) and the Student’s t test
(for continuous variables) to determine whether
differences were significant across the exposure
categories. We estimated unadjusted differences
in the outcomes using the Student’s t test to
compare LOS, hospitalization costs, and mean
opioid dose, while unadjusted logistic
regression was utilized to compare the
differences in rates of each of the potential
opioid-related adverse events (AEs). These
comparisons of outcomes were performed on
the entire cohort as well as stratified by surgery
type. We also compared the hospital
department-level costs using the Student’s
t test to estimate the differences in costs to
individual hospital department budgets.
We performed a two-stage least squares
regression instrumental variable analysis
overall and by surgery type. Such a regression
closely replicates randomization through an
exogenous factor (instrument). We estimated
each hospital’s rate of IV acetaminophen use for
all admissions on a quarterly basis as the
instrument. We constructed separate adjusted
two-stage least squares regression models for
LOS, total hospitalization cost, and opioid dose.
Use of IV acetaminophen (yes/no) was the main
independent variable, instrumented by the
time-varying quarterly rate of use of IV
acetaminophen. Each model was adjusted for
available confounding variables including age,
sex, race/ethnicity, APR-DRG severity of illness
and risk of mortality indexes, year of surgery,
and hospital characteristics: Bed size, whether it
was rural or urban, whether it was an academic
teaching hospital, and surgeon type (general,
orthopedic, or other). All analyses were
conducted using SAS for Windows, version 9.3
(SAS Institute Inc., Cary, NC, USA) and STATA
13 (StataCorp LP, College Station, TX, USA).
This study was approved by the Human
Subjects Division at the University of
Washington by self-determination by the
principal investigator.
RESULTS
We identified 4,85,895 orthopedic surgery
patients who were eligible for our study of
which 1,74,805 (36%) had been managed with
IV acetaminophen and opioids and 3,11,090
(64%) had been managed with IV opioids alone.
The subjects in both groups were an average of
64 years of age and slightly more than half were
female (58%) and nearly 80% of both groups
were white. The IV acetaminophen group
contained a higher proportion of elective
surgery patients (78.0% vs. 67.7%) and as such
the distribution of those patients on the
APR-DRG severity of illness and risk of
mortality scales was also higher on the minor
categories compared to IV opioid monotherapy
patients. Surgery type also differed between the
groups, with more total knee and hip
replacements occurring in the IV
acetaminophen group than the opioids group
(36.8% vs. 21.4% and 19.2% vs. 12.9%,
respectively; Table 1).
Our unadjusted analyses revealed
statistically significant differences across all of
the outcomes we investigated. The use of IV
acetaminophen was associated with -0.66
[95% confidence interval (CI) -0.68 to -0.64]
shorter days LOS, -$902.7 (95% CI -1005.4 to
-800.0) lower hospitalization costs, yet slightly
higher opioid dose of 3.1 mg MED (95% CI 2.8
to 3.4). Rates of respiratory depression, surgical
site infections, and urinary tract infections were
all significantly lower for patients who received
IV acetaminophen (all P\0.0001); however,
nausea/vomiting (P\0.0001) and bowel
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Table 1 Demographic characteristics of orthopedic surgery patients, comparing IV acetaminophen (Oﬁrmev) recipients to
IV opioid monotherapy recipients
Characteristic IV opioids (n5 3,11,090) IV acetaminophen (n5 1,74,805)
Age (years), mean (SD) 64.3 (15.6) 63.6 (14.0)
Female, n (%) 1,79,779 (57.8) 1,02,864 (58.8)
Race, n (%)
White 2,38,421 (76.6) 1,40,748 (80.5)
Black 24,876 (8.0) 14,591 (8.4)
Hispanic 47,600 (15.3) 19,362 (11.1)
Unknown 193 (0.1) 104 (0.1)
APR-DRG severity of illness, n (%)
Minor 1,36,264 (43.8) 80,801 (46.2)
Moderate 1,30,231 (41.9) 77,862 (44.5)
Severe 36,973 (11.9) 14,462 (8.3)
Extreme 7622 (2.5) 1680 (1.0)
APR-DRG risk of mortality, n (%)
Minor 2,17,279 (69.8) 1,37,283 (78.5)
Moderate 63,080 (20.3) 28,648 (16.4)
Severe 24,654 (7.9) 7454 (4.3)
Extreme 6077 (1.9) 1420 (0.8)
Elective surgery, n (%) 2,10,663 (67.7) 1,36,318 (78.0)
Hospital region, n (%)
Midwest 60,685 (19.5) 27,639 (15.8)
Northeast 70,154 (22.6) 28,530 (16.3)
South 1,32,013 (42.4) 1,04,113 (59.6)
West 48,238 (15.5) 14,523 (8.3)
Surgery type, n (%)
Total knee replacement 66,725 (21.4) 64,399 (36.8)
Total hip replacement 40,140 (12.9) 33,541 (19.2)
Knee revision 5187 (1.7) 4869 (2.8)
Hip revision or partial replacement 26,672 (8.6) 9671 (5.5)
Fracture 64,395 (20.7) 17,928 (10.3)
Othera 1,07,971 (34.7) 44,397 (25.4)
APR-DRG all patient reﬁned-diagnosis related group, IV intravenous, SD standard deviation
a Shoulder and spine
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obstruction (P = 0.4) were slightly higher
(Table 2). Stratification of costs by hospital
department revealed statistically significant
differences in all departments except
pharmacy. The IV acetaminophen group did
have higher costs classified under anesthesia
($15) and central supply ($763). But these were
offset by higher costs in the IV opioid
monotherapy group including surgery ($425),
room and board ($786), diagnostic imaging
($110), and respiratory therapy ($53; Fig. 1).
The instrumental variable regressions
estimated for LOS, costs, and opioid dose all
found statistically significant differences in
favor of the group who received IV
acetaminophen. Subjects who received IV
acetaminophen were estimated to have 0.51
less days in the hospital (95% CI -0.58 to
-0.44), cost $634.8 less (95% CI -1032.5 to
-237.1), and used 1.9 mg MED less in opioids
(95% CI -3.0 to -0.75; Table 3). Subgroup
analyses by surgery type revealed that LOS was
consistently lower across all surgery groups,
though only the fracture and other subgroups
were statistically and significantly lower. These
subgroup analyses also showed that while costs
were estimated to be lower for most groups,
they were slightly higher for total knee
replacements and other surgeries, none of
which were statistically and significantly
different. Opioid dose was also lower for all
groups (non-significant with the exception of
other) except MED was slightly higher for knee
revisions (1.1 mg, P = 0.8; Fig. 2).
DISCUSSION
We found that post-operative pain control with
IV acetaminophen and IV opioids in orthopedic
surgeries is associated with statistically and






Difference (95% CI) P value
Length of stay (days),
mean (SD)
3.9 (3.9) 3.2 (2.6) -0.66 (-0.68 to -0.64) \0.0001
Hospitalization cost ($),
mean (SD)
19,927.6 (19,578.8) 19,024.9 (13,113.7) -902.7 (-1005.4 to -800.0) \0.0001
Morphine equivalent dose
(mg), mean (SD)
43.8 (53.4) 46.9 (44.5) 3.1 (2.8 to 3.4) \0.0001
Opioid-related AEs, ORa (95% CI)
Urinary tract infection 0.596 (0.56 to 0.63) \0.0001
Respiratory depression 0.518 (0.50 to 0.54) \0.0001
Surgery site infection 0.754 (0.71 to 0.80) \0.0001
Bowel obstruction 1.013 (0.99 to 1.04) 0.4
Nausea/vomiting 1.208 (1.16 to 1.26) \0.0001
AE adverse event, CI conﬁdence interval, OR odds ratio, IV intravenous, SD standard deviation
a IV opioid monotherapy is the reference group
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significantly shorter LOS, decreased opioid
utilization, and lower hospitalization costs
compared to IV opioid monotherapy.
Reducing the hospital stay by one half day
and cost by over $600 are meaningful to both
patients and health systems. Hospital
department-level costs were also significantly
different between the groups, with anesthesia
and central supply higher for those who
received IV acetaminophen and IV opioids but
all other departments, with the exception of
pharmacy, higher for the group that received IV
opioid monotherapy. The largest
department-level differences were observed in
Fig. 1 Distribution of costs by hospital department comparing IV acetaminophen recipients to IV opioid monotherapy
recipients. IV intravenous
Table 3 Instrumental variable regression estimated outcomes of orthopedic surgery patients, comparing IV acetaminophen
recipients to IV opioid monotherapy recipients
Outcome Model estimate (95% CI) P value
Length of stay (days) -0.51 (-0.58 to -0.44) \0.0001
Hospitalization cost (US $) -634.8 (-1032.5 to -237.1) 0.0018
Morphine equivalent dose (mg) -1.9 (-3.0 to -0.75) 0.0011
CI conﬁdence interval, IV intravenous
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room and board, attributable in part to the LOS
difference between the groups, and central
supply, which as a catch-all department
pooled across hundreds of hospitals is difficult
to characterize. Surgical department cost
differences were also high, which could
Fig. 2 Instrumental variable regression estimated
outcomes between IV acetaminophen recipients and IV
opioid monotherapy recipients by surgery type. a Length of
stay; b total hospitalization costs; c morphine equivalent
dose. IV intravenous
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possibly be attributed to greater surgeon
follow-up time for the patients in the IV
opioid monotherapy group. Yet it is important
for within hospital department budget holders
to recognize that cost-shifting may occur in
surgical patient populations which ultimately
improve overall costs but may negatively
impact a given department’s budget.
Based on these analyses, introducing IV
acetaminophen into the multimodal analgesia
protocols for orthopedic surgery centers would
be expected to not only decrease costs but also
increase patient throughput. Furthermore,
finding that 64% of patients had been
managed with IV opioids alone (with
significant regional variation) speaks current
reliance on opioids and an opportunity for
patients, clinicians, and hospital systems to
increase dialog regarding multimodal analgesia
treatment options.
These findings are consistent with prior
research in both orthopedic and other surgical
procedures [10–13]. The body of literature
regarding the use of IV acetaminophen for
post-operative pain consistently finds
associations with lower costs and shorter LOS
for orthopedic surgery patients [10, 12, 13].
Importantly, the population of orthopedic
surgery patients in the Premier Database was
quite diverse and we observed meaningful
differences between the groups of patients
who received IV opioid monotherapy
compared to those who received both IV
acetaminophen and IV opioids
post-operatively. We feel that through the use
of the instrumental variable approach, our
analyses have controlled for selection bias as
much as possible outside of a randomized trial,
which would be impractical in the size and
scope of the population we have currently
studied.
Limitations
This study retains some limitations that should
be considered when interpreting our findings.
First, we cannot be certain that the differences
we observed between IV acetaminophen and IV
opioid monotherapy patients could not be
explained by unobserved confounding factors.
We attempted to account for this through the
use of instrumental variable regression,
adjusting our models for potentially
confounding variables, but unmeasured factors
might still play a role in the associations that we
reported. Second, the medication use data in
Premier is based on the amount and dose
charged rather than what was exactly
administered to the patient. However, we do
not suspect systematic differences in billing of
opioids between patients who did or did not
receive IV acetaminophen. Third, while we
performed unadjusted comparisons of surgical
complications, methods do not exist to perform
two-stage instrumental variable regressions
with logistic regression in the second stage.
Therefore, we were limited in our ability to draw
conclusions regarding the impact of IV
acetaminophen on complications. Finally, the
population of patients seen in premier hospitals
is not randomly sampled. Therefore, these
results may not be generalizable outside of
Premier hospitals.
CONCLUSIONS
We observed clinically and economically
important differences in LOS, hospitalization
costs, and opioid utilization among orthopedic
surgery patients who were managed with IV
acetaminophen compared to IV opioids alone.
In support of guidelines by the American Pain
Society [9], clinicians should consider
Adv Ther (2016) 33:1635–1645 1643
multimodal post-operative pain management
including IV acetaminophen for orthopedic
surgeries.
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